Cancer - Adaptimmune

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05601752

A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS

Drug

ADP-A2M4CD8

Condition

Ovarian cancer

Keywords

Ovarian cancer